公开(公告)号：US20220396797A1

公开(公告)日：2022-12-15

申请号：US17777255

申请日：2020-11-13

Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE

Inventor： Malcolm S. DUTHIE ,  Steven G. REED

IPC: C12N15/117 ,  A61P35/00 ,  A61K9/107

Abstract: Cancer immunotherapies effective for treating tumors are disclosed. A cytosolic receptor that detects viral ribonucleic acid (RNA), retinoic-acid-inducible protein 1 (RIG-I), is activated by a synthetic double-stranded oligonucleotide pUUC Auk. In one implementation, RIG-I is activated by a single-stranded oligonucleotide agonist formulated with a squalene emulsion (SE) adjuvant. Activation of RIG-I with pUUC Auk results in slower tumor growth. Formulation with a SE adjuvant increases the ability of RIG-I agonists to slow tumor growth. The novel agonist and formulations provided herein are effective for slowing the growth of new tumors and reducing further growth of established tumors. RIG-I agonist/adjuvant formulations may be administered to a subject by any of multiple routes including intratumoral injection.